BioStock:Progress in Q4 sets tone for Cyxone in 2021

Biotech company Cyxone recently published its fourth quarter result, a period with great focus in the advancement of the project with the drug candidate Rabeximod. The company filed for new patents, presented positive results from a toxicology study and received approval to begin a phase II trial in patients with moderate Covid-19. During the quarter, the company also strengthened its cash balance to fund all planned activities in 2021. BioStock reached out to CEO Tara Heitner for some additional comments.

Read the full interview with Cyxone's CEO Tara Heitner at biostock.se:

https://www.biostock.se/en/progress-in-q4-sets-tone-for-cyxone-in-2021/

This is a pressrelease from BioStock - Connecting Innovation & Capital. https://www.biostock.se/